cannabinoid receptor


Also found in: Wikipedia.

cannabinoid receptor

THC receptor, see there.
References in periodicals archive ?
Lenabasum is a rationally designed, oral, small molecule that selectively binds as an agonist to the cannabinoid receptor type 2 (CB2) and has been designed to resolve inflammation, limit fibrosis and support tissue repair.
A professor of Chemistry and Chemical Biology in the Department of Medicinal Chemistry at Northeastern University, Makriyannis is credited with numerous scientific cannabinoid-centric achievements, including the discovery of cannabinoid receptor antagonists, as well as pioneering inmetabolically stable endocannabinoids.
Cannabinoid receptor type 1 (CB1) are mostly found in the brain, and also in the male and female reproductive systems.
presented new Phase 2 data from its investigative drug candidates etrasimod, a next-generation, oral, selective sphingosine 1 phosphate (S1P) receptor modulator in development for the treatment of moderate to severely active ulcerative colitis (UC), and olorinab, a peripherally restricted, highly selective, full agonist of the cannabinoid receptor type 2 (CB2) in development for the treatment of visceral pain associated with gastrointestinal (GI) diseases, at the 14thCongress of European Crohn's and Colitis Organisation (ECCO).
Under the contract, Opiant is likely to develop drinabant, a cannabinoid receptor type 1 (CB-1) antagonist, as an injection that can be used in an emergency.
After adjustment for this factor, there were lower estimates of ASD risk among children exposed to cannabinoid receptor agonists, muscarinic receptor 2 agonists, opioid receptor ?
This difference in pathways may explain why in animal models of neuropathic pain cannabinoid receptor agonists last longer compared with morphine.
Raphael Mechoulem, an Israeli scientist at Hebrew University started to identify cannabinoid like structures (produced endogenously) and the bodies cannabinoid receptor system.
as senior scientist with Cannabics Pharmaceuticals Inc., a Bethesda-based firm that develops cannabinoid diagnostic tests for the personalized treatment of cancer.<br />The two new team members will support Cannabics' data-discovery process with the goal of identifying new cannabinoid diagnostic tests and treatments for cancer.<br />Sharir is widely recognized for her role in identifying a potentially new cannabinoid receptor, GPR55.
SCBs and THC both bind to cannabinoid receptor type 1 ([CB.sub.1]) and cannabinoid receptor type 2 ([CB.sub.2]).
Studies that did not use animals, did not evaluate CINP, or evaluated noncannabinoid compounds without using cannabinoid receptor antagonists, reviews, commentaries, and in vitro studies were excluded.